Home
Site Map
Contact Us
Graphics Version
Printer Version
Main Navigation
ABOUT US
COMPANY PROFILE
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGY
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
MANAGEMENT TEAM
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
BOARD OF DIRECTORS
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
CONTACT US
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
THERAPEUTIC FOCUS
CARDIOVASCULAR
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
CNS
Huntington's Disease
Myasthenia Gravis
Parkinson's Disease
Epilepsy
PRODUCTS
PIPELINE
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 for Hypertriglyceridemia
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 for HD
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
EN101
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
SUBLINGUAL APOMORPHINE
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
NASAL LORAZEPAM
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
AMR103
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
SCIENCE & TECHNOLOGY
INTRODUCTION
Lipophilic Platform
Targeted Lipid Transport Technology Platform
Cholinergic Platform
PARTNERING
PARTNERING
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
BUSINESS DEVELOPMENT
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGIC ALLIANCES
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
STOCK INFORMATION
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
CORPORATE GOVERNANCE
AUDIT COMMITTEE
REMUNERATION COMMITTEE
LEAD INDEPENDENT DIRECTOR
CODE OF ETHICS
MEMORANDUM AND ARTICLES OF ASSOCIATION
PRESENTATIONS
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
PRESS RELEASES
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR FAQ
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
REQUEST INVESTOR KIT
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
FINANCIAL REPORTS
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
SEC FILINGS
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
AGM 2008
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
EGM 2008
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
AGM 2007
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
ANALYST COVERAGE
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
EMAIL ALERTS
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
REQUEST INFORMATION
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
STOCK INFORMATION
CORPORATE GOVERNANCE
PRESENTATIONS
PRESS RELEASES
Recent
2008
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
INVESTOR FAQ
REQUEST INVESTOR KIT
FINANCIAL REPORTS
SEC FILINGS
AGM 2008
EGM 2008
AGM 2007
ANALYST COVERAGE
EMAIL ALERTS
REQUEST INFORMATION
Mailing List
Join our mailing list if you wish to receive updates by email
Mailing List
Unsubscribe »
INVESTOR
RELATIONS
PRESS RELEASES
1-Jul-2009
Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
10-Jun-2009
Amarin Announces Results From Exploratory Phase 2a Study Of EN101 In Myasthenia Gravis
26-May-2009
Amarin Announces $2.6 Million Bridge Financing
6-May-2009
Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Cardiovascular Trial
8-Apr-2009
Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for review by EMEA
11-Mar-2009
Amarin To Present At The Cowen & Company 29th Annual Health Care Conference
3-Feb-2009
Amarin To Present At The 11th Annual BIO CEO & Investor Conference
Web Design by Webtrade.ie